Selective Inhibition of Cyclooxygenase (COX)-2 Reverses Inflammation and Expression of COX-2 and Interleukin 6 in Rat Adjuvant Arthritis

Gary D. Anderson,* Scott D. Hauser,† Kelly L. McGarity,* Margaret E. Bremer,* Peter C. Isakson,* and Susan A. Gregory†

Departments of *Inflammatory Diseases Research and †Cell and Molecular Biology, G.D. Searle & Company, St. Louis, Missouri 63198

Abstract

Prostaglandins formed by the cyclooxygenase (COX) enzymes are important mediators of inflammation in arthritis. The contribution of the inducible COX-2 enzyme to inflammation in rat adjuvant arthritis was evaluated by characterization of COX-2 expression in normal and arthritic paws and by pharmacological inhibition of COX-2 activity. The injection of adjuvant induced a marked edema of the hind footpads with coincident local production of PGE₂. PG production was associated with upregulation of COX-2 mRNA and protein in the affected paws. In contrast, the level of COX-1 mRNA was unaffected by adjuvant injection. TNF-α and IL-6 mRNAs were also increased in the inflamed paws as was IL-6 protein in the serum. Therapeutic administration of a selective COX-2 inhibitor, SC-58125, rapidly reversed paw edema and reduced the level of PGE₂ in paw tissue to baseline. Interestingly, treatment with the COX-2 inhibitor also reduced the expression of COX-2 mRNA and protein in the paw. Serum IL-6 and paw IL-6 mRNA levels were also reduced to near normal levels by SC-58125. Furthermore, inhibition of COX-2 resulted in a reduction of the inflammatory cell infiltrate and decreased inflammation of the synovium. Notably, the antiinflammatory effects of SC-58125 were indistinguishable from the effects observed for indomethacin. These results suggest that COX-2 plays a prominent role in the inflammation associated with adjuvant arthritis and that COX-2 derived PGs upregulate COX-2 and IL-6 expression at inflammatory sites. (J. Clin. Invest. 1996. 97:2672–2679.) Key words: eicosanoid • cytokine • prostaglandin • cyclooxygenase • inflammation

Introduction

Prostaglandins are important lipid mediators that are produced at elevated levels in inflamed tissues including rheumatoid synovium (1, 2). PGE₂ and PGI₂ likely contribute to synovial inflammation by increasing local blood flow and potentiating the effects of mediators such as bradykinin and IL-1 that induce vasopermeability (reviewed in reference 3). PGE₂ has also been shown to trigger osteoclastic bone resorption (4), suggesting that this molecule may contribute to the pathophysiology of joint erosion in chronic arthritic diseases. PGs are products of the cyclooxygenase (COX) pathway of arachidonic acid metabolism. Two isoforms of the COX enzyme have recently been identified. COX-1 is constitutively expressed in a variety of cells and tissues (5). The other isofrom, COX-2, is the product of an immediate early response gene in inflammatory cells. The expression of COX-2 is induced by endotoxins, mitogens, or cytokines including IL-1 and TNF-α in cultured macrophages, fibroblasts, endothelial cells, and chondrocytes (6–13). In addition, both IL-1 and TNF-α enhance production of PGE₂ and COX-2 by synoviocytes from rheumatoid arthritis and osteoarthritis patients (14–17). Induction of cellular COX-2 biosynthesis is inhibited by dexamethasone (10, 13–16, 18–21), suggesting that endogenous corticosteroids may exert some negative regulatory effects on local inflammatory PG production.

Regulation of COX-2 gene expression has been documented in both human and rodent synovial tissues. Before the identification of selective probes for each COX isoform, Sano et al. (22) observed intense intracellular COX immunostaining in synovial lining cells, fibroblasts, and macrophages of rheumatoid arthritis patients, while osteoarthritis synovia showed weak and diffuse COX staining and staining was absent in normal synovial tissue. COX immunostaining was also observed in inflamed paw tissue from Lewis rats with streptococcal cell wall- or adjuvant-induced arthritis; staining was absent in normal paw tissue. The level of COX expression was found to parallel the development of clinical disease and correlate with synovial mononuclear cell infiltration in experimentally induced arthritis. Furthermore, this study showed that treatment with dexamethasone prevented the high level expression of COX protein in synovial tissue, suggesting that the inducible COX-2 enzyme is selectively upregulated in arthritic tissues. Crofford et al. (14) extended those findings by demonstrating that IL-1β enhanced de novo synthesis of COX-2 but not COX-1 mRNA and protein in rheumatoid synovial explants and cultured rheumatoid synoviocytes. Selective upregulation of COX-2 mRNA and protein has also recently been demonstrated in rodent air pouch models of acute granulomatous inflammation (23, 24). Taken together, these findings suggest that the enhanced production of PGs in both acutely and chronically inflamed tissues results from selective, local upregulation of COX-2 biosynthesis.

Nonsteroidal antiinflammatory drugs (NSAIDs), including indomethacin, are effective antiinflammatory and analgesic agents commonly used in the treatment of rheumatoid arthritis and osteoarthritis. NSAIDs inhibit PG formation through inhibition of both the COX-1 and COX-2 enzymes (25, 26). Long-term NSAID treatment is often limited, however, by gastrointestinal ulcerogenicity that may result from the suppression of...
physiological PG production in these tissues. We have recently demonstrated the ability of a selective COX-2 inhibitor to block PG production (23) and acute tissue inflammation (27) in vivo at dosages that do not affect stomach PG production, suggesting that COX-2 inhibitors may provide a safer therapeu-
tic alternative to NSAIDs. In this report, we tested the hy-
pothesis that inflammatory PG production in chronic arthritis is regulated through selective upregulation of COX-2 in syn-
ovial tissue. We used the Lewis rat model of adjuvant-induced arthritis to survey the expression of COX-1 and COX-2 through-
out the disease process and to examine the therapeutic antiin-
fiammatory effects of the selective COX-2 inhibitor SC-58125.
Our data indicate that COX-2 but not COX-1 is upregulated in
tpaw tissue concomitant to the development of edema in this
model and that selective inhibition of COX-2 rapidly reverses
PG production and edema in arthritic paws. In addition, selec-
tive inhibition of COX-2 activity downregulates COX-2 and
IL-6 production in arthritic paws and suppresses the systemic
production of IL-6 induced by adjuvant.

Methods

Induction of arthritis. Arthritis was induced in male Lewis rats (125–
150 g; Harlan Sprague Dawley, Indianapolis, IN) by injection of 1 mg
of M. butyricum (Difco Laboratories Inc., Detroit, MI) in 50 µl of
mineral oil (Mallinkrodt, Paris, KY) into the right hind footpad (28).
14 d after injection of adjuvant, the contralateral left footpad volume
was measured with a water displacement plethysmometer. Animals
with paw volumes 0.37 ml greater than normal paws were then ran-
domized into treatment groups. Drug administration was begun on
day 15 post-adjuvant injection and continued until final assessment
on day 25. During this period contralateral paw volume measure-
ments were taken intermittently. Some animals were also killed such
as to determine the volume of edema in this model and that selective inhibition of COX-2 rapidly reverses
PG production and edema in arthritic paws. In addition, selec-
tive inhibition of COX-2 activity downregulates COX-2 and
IL-6 production in arthritic paws and suppresses the systemic
production of IL-6 induced by adjuvant.

Methods

Induction of arthritis. Arthritis was induced in male Lewis rats (125–
150 g; Harlan Sprague Dawley, Indianapolis, IN) by injection of 1 mg
of M. butyricum (Difco Laboratories Inc., Detroit, MI) in 50 µl of
mineral oil (Mallinkrodt, Paris, KY) into the right hind footpad (28).
14 d after injection of adjuvant, the contralateral left footpad volume
was measured with a water displacement plethysmometer. Animals
with paw volumes 0.37 ml greater than normal paws were then ran-
domized into treatment groups. Drug administration was begun on
day 15 post-adjuvant injection and continued until final assessment
on day 25. During this period contralateral paw volume measure-
ments were taken intermittently. Some animals were also killed such
that the left (contralateral) paw could be examined histologically and
level of PG, COX, and cytokines could be measured. The typ-
ical increase in contralateral paw volume measured on day 25 ranged
from 1.4 to 1.9 ml.

Drug treatment. Dexamethasone and indomethacin were pur-
chased from Sigma Chemical Co., St. Louis, MO. The selective inhib-
itor of COX-2, SC-58125: [1-(4-methylsulfonyl)phenyl]-3-trifluoro-
methyl-5-[[4-fluoro]phenyl] pyrazole] was synthesized at G.D. Searle
& Co. (St. Louis, MO). SC-58125 potently inhibits the recombinant
mouse COX-2 enzyme (IC₅₀ = 0.07 µM) without inhibiting COX-1
(IC₅₀ > 100 µM) (27). SC-58125 potently inhibits COX-2 in IL-1-
stimulated human fibroblasts (IC₅₀ = 0.09 µM) without affecting human
platelet COX-1 (IC₅₀ = 8.8 µM). Oral administration of SC-58125 to
Lewis rats at a dosage of 3 mg/kg has no effect on physiological PG
production in the stomach (27) or on platelet COX-1 activity, mea-
sured ex vivo as A23187-induced thromboxane B2 (TXB2) produc-
tion in whole blood. Compounds were prepared as a suspension in
0.5% methylcellulose, 0.025% Tween 80 (Sigma Chemical Co.). Ani-
mals were dosed twice daily by gavage at the indicated dosages in a
volume of 1.0 ml/d.

Paw sample preparation. After death, paws from arthritic and
normal animals were amputated above the ankle, degloved, and
snapfrozen in liquid nitrogen. Frozen paws were pulverized in a liquid
nitrogen bath and divided into aliquots for extraction and analysis of
PG, COX, and cytokine mRNAs and COX-2 protein. Samples were
stored at ~70°C until used.

RNA preparation and nucleic acid analysis. Samples of total
RNA (5 µg) (29) were hybridized with 32P-labeled antisense RNA
probes. Specific mRNAs were quantified by nucleic acid previ-
ously described (23). The rat COX-2 probe was graciously provided by P.
Worley, Johns Hopkins School of Medicine, Baltimore, MD. cDNA
fragments of rat COX-1 (23), IL-6, and TNF-α were cloned by re-
verse transcriptase–PCR amplification from RNA obtained from carr-
geranean-stimulated air pouch tissue. Oligonucleotide primers were as
follows: rat IL-6 forward GTACGACCTGGAGAATCTCAA-
GAGTACCC and reverse GATCGACCATGTTATATCCAG-
TTGGGAAGCTC; rat TNF-α forward GTAGCAAGGCCTCA-
GGATCTCAAGAAGCAC and reverse GATCGAGGAT-
CCAGGCTGTAGGCTCGTCC. The rat GADPH template
was purchased from Ambion Inc. Fragments were subcloned into
pGEM™ vectors (Promega Corp., Madison, WI). Antisense probes
were transcribed using the appropriate RNA polymerase from plas-
mid templates linearized with enzymes that cut in the poly-linker ad-
jacent to the 3′ end of the insert. Probes were synthesized using re-
agents from Promega and d[3P]CTP from New England Nuclear
(Boston, MA). Relative intensities of each RNA were determined us-
ing a phosphorimager (Molecular Dynamics Inc., Sunnyvale, CA).

COX-2 protein extraction and analysis. The mouse COX-2–specific
L8 and R6 mouse mAbs (30) were produced by J. Pegg at G.D.
Searle & Co. Both L8 and R6 antibodies demonstrate > 1,000-fold
selectivity for mouse COX-2 compared to mouse COX-1 in solid-
phase capture RlAs and in competition binding RlAs (30). Pulver-
ized frozen paw tissue (0.3–1 g) was added to 2 ml of PBS containing
1% CHAPS (Sigma Chemical Co.). The tissue was solubilized for 24 h
at 4°C with gentle rocking and then centrifuged at 200 g for 15 min to
clear cell debris. COX-2 protein was quantified by ELISA (30), Mi-
crowell plates (Dynatek Laboratories Inc., Chantilly, VA) were
coated with 200 µl of mouse anti–mouse COX-2 mAb L8 (1 µg/ml in
borate-buffered saline) for 1 h and then blocked with 1% BSA in
PBS containing 0.5% Tween 20. Plates were washed three times with
0.5% Tween-PBS, and 50 µl of a purified mouse COX-2 standard
(provided by J. Gierse, G.D. Searle & Co.) or tissue extract was
added for 1 h. Plates were again washed, and 200 µl of horseradish
peroxidase–conjugated R6 anti–mouse COX-2 mAb (10 µg/ml) was
added for 1 h. After thorough washing, 200 µl ABTS (2,2′-azino-di-[3-
ethylbenzthiazoline sulphonate (6)]) substrate (Kirkegaard and Perry
Laboratories, Inc., Gaithersburg, MD) was added, and absorbance
was measured at 405 nm. The level of COX-2 protein in each sample
was estimated by comparison of optical density to that of a COX-2
standard. The sensitivity of the COX-2 ELISA was 6.25 ng/ml. Total
sample protein was determined using the DC Protein Assay Kit (Bio-
Rad Laboratories, Hercules, CA), and COX-2 protein levels were
expressed as nanograms COX-2 per milligram protein.

Prostaglandin extraction and analysis. Frozen paw tissue (~ 0.5 g)
was homogenized by polytron in 1 ml methanol and again after the
addition of 1 ml water. The samples were adjusted to 10% methanol
with water and allowed to precipitate on ice for 20 min. Precipitated
material was pelleted by centrifugation at 4°C for 20 min. The super-
natants were applied to a C-18 Sep-Pak cartridge (Waters Division of
Millipore Corporation, Milford, MA) that was preconditioned with
methanol followed by water. After loading the supernatants, the col-
umns were sequentially washed with water, 10% methanol, and pe-
roleum ether. The samples were eluted with methyl formate and
evaporated under nitrogen. Samples were reconstituted in ELISA
buffer and assayed for PGE2 by ELISA (Cayman Chemicals, Ann
Arbor, MI). The sensitivity of the PGE2 ELISA was 20 pg/ml.

IL-6 bioassay. Rat blood was obtained from the retroorbital sinus
and allowed to clot for 1 h at room temperature. Serum was recovered
and frozen at ~70°C until assayed. Serum samples were assayed for
their ability to support the proliferation of the IL-6–dependent 7TD1
plasmacytoma cell line as previously described (31). Results were es-
timated by four parameter regression of best line fit to a standard
curve using recombinant mouse IL-6 (Genzyme Corp., Cambridge,
MA) and expressed as units per milliliter. 1 U/ml produced half-
maximal cell proliferation and was equivalent to ~ 10 pg/ml of IL-6.

Histological evaluation of hind limb joints from arthritic paws.
The left hind limb was removed below the stifle joint, degloved, and
fixed in 1% formaldehyde in saline. The limbs were decalcified, pro-
cessed, embedded in paraffin, sectioned, and stained with hematoxy-
lin and eosin. Sections of the paw were made in a mid-sagittal plane.
Articulations of the tarsal and metatarsophalangeal joints were ex-
amined microscopically. Within each joint the synovium, cartilage,
bone and soft tissue were examined for synovial hyperplasia, inflam-
mation, bone and cartilage destruction, edema and pannus formation.

Results

Expression of COX-2 and production of PGE2 in rat adjuvant
arthritis. The temporal relationship between COX expression,
PG production, and the development of arthritis was exam-
ined in adjuvant-injected Lewis rats and is shown in Fig. 1. An
increase in contralateral paw volume was evident 11–14 d after
adjuvant injection (Fig. 1A). Paw edema occurred concomi-
tant with or immediately after the rapid induction of COX-2
mRNA, COX-2 protein, and PGE2 in the affected paws (Fig.
1, B–D, respectively). The level of COX-2 mRNA increased
four to fivefold over levels found in normal paws and was sus-
tained through day 25, whereas the level of COX-1 mRNA in-
creased less than twofold. The amount of COX-2 protein in af-

Figure 1. Induction of paw edema, COX-2 mRNA and protein,
and PGE2 during adjuvant-induced ar-
thritis. On day 0, M. butyricum
was injected subcutaneously in the
plantar surface of the right hind-
paw. At intervals thereafter,
edema in the contralateral paw
was measured as increased paw
volume (A) by plethysmometry.
Paw tissue samples were also re-
covered for extraction and analy-
sis. B shows the levels of COX-1
(squares), COX-2 (circles), and
GAPDH (triangles) mRNAs de-
tected in paw extracts by nuclease
protection analysis. The levels of
COX-2 protein (ng/mg protein; 
C), and PGE2 (nanogram per
gram paw tissue; D) in tissue
extracts were determined by
ELISAs. Data is presented as the
group mean ± SEM (n = 3 animals
per group).

Figure 2. Reversal of paw edema after
oral administration (b.i.d., i.g.) of SC-
58125 (3 mg/kg; open squares), in-
domethacin (2 mg/kg; open diamonds), or
dexamethasone (0.1 mg/kg; open circles).
Male Lewis rats were injected with M.
butyricum on day 0, and arthritic animals
were randomized into treatment groups
on day 14. Administration of compounds
began on day 15. At intervals thereafter,
edema in the contralateral paw was mea-
sured as increased paw volume by ple-
thesmometry. The paw volumes recorded
for normal (closed circles) and injected,
vehicle-treated (closed squares) control
animals are included for comparison.
Data is presented as group mean ± SEM
(n = 8 animals per group).
fected paws increased dramatically between days 8 and 14 and was accompanied by a sharp three to sixfold increase in the level of PGE\(_2\) in the paw; elevated levels of both COX-2 and PGE\(_2\) were sustained through day 25. These data indicate that the development of arthritis was associated with selective up-regulation of COX-2 mRNA and protein biosynthesis and production of PGE\(_2\) in the affected paw tissue.

**Effect of SC-58125 on paw inflammation and PGE\(_2\) production in arthritic paws.** We next evaluated the antiinflammatory effects of a selective inhibitor of COX-2, SC-58125, on established arthritis. As shown in Fig. 2, oral administration of SC-58125 (3 mg/kg) to arthritic rats rapidly reversed paw edema as did indomethacin and dexamethasone. After 10 d of treatment paw swelling was reduced in the SC-58125 treated animals by 80–85% relative to the paw volume of vehicle-treated animals (Fig. 3 A). The antiinflammatory effect of SC-58125 was equivalent to that observed after treatment with indomethacin (2 mg/kg), while dexamethasone (0.1 mg/kg) inhibited paw edema by 95–100%. For all treatments, the reduction in paw edema was associated with a pharmacological reduction in PG production in arthritic paws (Fig. 3 B). Treatment with SC-58125 reduced the level of PGE\(_2\) in arthritic paws to near normal levels as did dexamethasone, suggesting that adjuvant-induced PG production is primarily mediated by COX-2 in the paw.

**Effect of SC-58125 on expression of COX-2 mRNA and protein in arthritic paws.** Unexpectedly, treatment of arthritic rats with SC-58125 decreased the level of COX-2 protein in arthritic paws (Fig. 3 C), as did indomethacin. Inhibition of PG production in the paws by the COX inhibitors was associated with a > 70% decrease in the level of COX-2 protein measured at day 25, suggesting that PG upregulate local COX-2 expression in the inflamed joint. The production of COX-2 protein was also attenuated by treatment with the glucocorticoid dexamethasone (Fig. 3 C). The mechanism by which these inhibitors suppressed COX-2 protein production was further investigated by determining the steady state level of COX-2 mRNA in arthritic paws after treatment. SC-58125 and indomethacin dramatically reduced the level of COX-2 mRNA measured in arthritic paws on day 25 without affecting the level of COX-1 mRNA (Fig. 4). As expected, treatment of arthritic rats with dexamethasone also reduced the level of COX-2 but not COX-1 mRNA in affected paws.

**Effect of SC-58125 on adjuvant-induced expression of TNF-\(\alpha\) and IL-6.** Since proinflammatory cytokines such as TNF-\(\alpha\) and IL-1 are known to induce expression of COX-2 in synovial cells in vitro, we examined whether the treatment-related decreases in COX-2 production were associated with decreased adjuvant-induced cytokine production in arthritic paws. As shown in Fig. 4, high levels of TNF-\(\alpha\) and IL-6 mRNAs were expressed in paws on day 25, while very low levels of these mRNAs were detected in normal paw tissue. Treatment with SC-58125 markedly attenuated IL-6 mRNA expression in the paw but had no substantial effect on the level of TNF-\(\alpha\) mRNA, suggesting that PGs selectively upregulate local cytokine expression in inflamed synovial tissue. The development of paw edema was associated with a dramatic increase in the level of IL-6 protein in serum (Fig. 5 A). The elevated level of IL-6 in the serum of arthritic rats persisted through day 25. Treatment with SC-58125 decreased the level of IL-6 in serum (Fig. 5 B), indicating that COX-2-mediated PG production supports the systemic inflammatory cytokine response in adjuvant-induced arthritis.
bone and joint and the surrounding soft tissue. Soft tissue pathology consisted of extensive neutrophil and macrophage infiltration, and cartilage and muscle destruction. The subchondral bone in most joints was severely eroded by abundant osteoclasts. Paws from animals treated with SC-58125 (Fig. 6C) or indomethacin (Fig. 6D) on days 15–25 showed a reduced but persistent inflammatory cell infiltrate. However, the number of osteoclasts present in the subchondral bone, tissue edema, and bone erosion in the paws were markedly reduced by both treatments, indicating that a selective inhibitor of COX-2 was as effective in retarding synovial inflammation and joint destruction as a nonselective COX inhibitor NSAID. Treatment with SC-58125 or indomethacin resulted in preservation of hyaline in the articular cartilage and a well defined tidemark separating the calcified cartilage. In addition, the

Figure 4. Nuclease protection analysis of adjuvant-induced COX-2, COX-1, TNF-α, and IL-6 mRNAs in normal paws and in arthritic paws after treatment (b.i.d., i.g.) on days 15–25 with SC-58125 (3 mg/kg), indomethacin (2 mg/kg), or dexamethasone (0.1 mg/kg). Paw tissues were recovered on day 25 post-adjuvant for extraction and analysis. The level of mRNAs were quantified by nuclease protection using specific rat antisense RNA probes; the level of GAPDH mRNA in each extract is shown for comparison.

Figure 5. Elevation of IL-6 in the serum in arthritic rats and inhibition of systemic IL-6 production by treatment with SC-58125 (3 mg/kg), indomethacin (2 mg/kg), or dexamethasone (0.1 mg/kg). Male Lewis rats were injected with M. butyricum on day 0. At intervals thereafter, serum samples were collected for quantitation of IL-6 bioactivity (A). Arthritic rats were treated (b.i.d., i.g.) on days 10–25, and the effect of treatment on the level of serum IL-6 bioactivity was determined on day 25 (B). IL-6 bioactivity (U/ml) was determined by support of murine 7TD1 cell proliferation and quantified by comparison to recombinant mouse IL-6. Data is presented as group mean±SEM (n = 3 animals per group).
Selective Inhibition of COX-2 Reverses Rat Adjuvant Arthritis

Subchondral bone was intact, and the number of osteoclasts in the subchondral and trabecular bone space was greatly reduced. Treatment with dexamethasone over the same period almost completely abolished the cellular infiltrate in the joint and restored normal joint morphology.

Discussion

The results of this study indicate that the development of synovial inflammation in experimentally induced arthritis is associated with a selective increase in the level of COX-2 mRNA.
This study also provides insight into the proinflammatory activities of COX-2-derived PGs in established arthritis. Oral administration of the selective COX-2 inhibitor SC-58125 to arthritic animals rapidly reversed paw edema, reduced joint inflammation and returned PGE₂ levels to normal. Furthermore, inhibition of COX-2 activity diminished the level of COX-2 mRNA in paw tissue without affecting the steady state level of COX-1 mRNA, suggesting that PGs enhance the local expression of COX-2 itself in inflamed synovial tissue. The antiinflammatory effects of SC-58125 were indistinguishable from the effects observed with indomethacin, a nonselective COX inhibitor, confirming that pharmacological inhibition of COX-2 underlies the suppression of PG production, edema, and COX-2 expression in adjuvant arthritis.

Inhibition of COX-2 activity also modulated local and systemic cytokine production in arthritic rats. The development of arthritis was associated with increased levels of TNF-α and IL-6 mRNAs in affected paws and systemic IL-6 production. Both cytokines have been shown to be produced spontaneously by rheumatoid arthritis synovial cells (34–37). Treatment of arthritic rats with SC-58125 or indomethacin markedly reduced the level of IL-6 mRNA in affected paws. Inhibition of COX-2 activity also reversed systemic IL-6 production in arthritic animals, suggesting that PGs provide a costimulatory signal for both local and systemic IL-6 production in adjuvant arthritis. Partial inhibition of systemic IL-6 production by treatment with indomethacin has been documented previously (38). Both enhancement and suppression of TNF-α production have been demonstrated to be dose dependently regulated by PGE₂ and cAMP in rat peritoneal macrophages (39), but we observed no significant change in the level of TNF-α mRNA in the paws of rats treated with SC-58125 or indomethacin. In contrast, treatment with dexamethasone markedly reduced the levels of both TNF-α and IL-6 mRNA in arthritic paws.

A short course of treatment with SC-58125 or indomethacin markedly reduced the cellular infiltrate in affected joints, inflammation of synovial tissue, and erosion of bone and cartilage. The ability of COX inhibitors to partially reduce the mononuclear infiltrate in arthritic joints could in part explain the observed reduction in the levels of COX-2 and IL-6 proteins in the paw, but the residual macrophage infiltrate still evident after 10 d of treatment suggests that de novo COX-2 and IL-6 production in the synovium was suppressed. In contrast to the COX inhibitors, treatment of arthritic animals with dexamethasone almost completely abrogated cellular infiltration of the joint, restoring normal joint morphology. This additional antiinflammatory effect may reflect the ability of dexamethasone to modulate the cellular immune response to adjuvant and to suppress PG-independent proinflammatory cellular responses in established disease.

Taken together, our findings support a model (Fig. 7) in which adjuvant induces local TNF-α, COX-2, and IL-6 production in the affected paws. COX-2-derived PGs appear to mediate a variety of proinflammatory effects in this model of arthritis, including enhancement of local plasma and cellular exudation and upregulation of IL-6 and COX-2 itself. Enhanced TNF-α expression did not correlate with COX-2 or IL-6 expression when PG synthesis was inhibited, however, suggesting that COX-2 and IL-6 are not induced by TNF-α in the inflamed synovium. Additional studies will be needed to determine whether the expression of COX-2 or IL-6 are dependent on IL-1 production in this model and whether PGs regulate

![Figure 7. Model for regulation of PG, COX-2, and cytokine expression in arthritic synovial tissue. Stimulation of synoviocytes leads to TNF-α release and recruitment of inflammatory cells to the affected joint. Resident and recruited inflammatory cells produce COX-2 and IL-6. COX-2–derived PGs feed back to upregulate the production of COX-2 and IL-6 in a para- or autoregulatory fashion without affecting the level of TNF-α.](http://www.jci.org)
the expression of IL-1 in inflamed synovial tissue. Overall, this study demonstrates that treatment of established adjuvant arthritis with a selective inhibitor of COX-2 produces anti-inflammatory effects that are qualitatively and quantitatively comparable to the nonselective COX inhibitor indomethacin. These findings suggest that proinflammatory PG production in chronic synovial inflammation is mediated primarily by the activity of the induced COX-2 enzyme and that selective COX-2 inhibitors will likely be as effective as NSAIDS in the treatment of arthritic diseases.

Acknowledgments

We thank D. Edwards and Dr. R. Ornberg for assistance with immunohistochemical analyses. We also thank Drs. P. Manning, J. Poratovana, K. Seibert, and W. Smith for their excellent critique.

References


Select Inhibition of COX-2 Reverses Rat Adjuvant Arthritis

2679


